NASDAQ:URGN - Urogen Pharma Stock Price, Forecast & News

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Urogen Pharma Ltd (NASDAQ:URGN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.20. View Urogen Pharma's Earnings History.

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Urogen Pharma.

Urogen Pharma will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 brokers have issued 1-year price objectives for Urogen Pharma's shares. Their forecasts range from $37.00 to $75.00. On average, they anticipate Urogen Pharma's stock price to reach $50.14 in the next year. This suggests a possible upside of 83.1% from the stock's current price. View Analyst Price Targets for Urogen Pharma.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.

Media headlines about URGN stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Urogen Pharma earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Urogen Pharma.

Urogen Pharma saw a increase in short interest in February. As of February 14th, there was short interest totalling 2,400,000 shares, an increase of 13.2% from the January 30th total of 2,120,000 shares. Based on an average daily trading volume, of 171,200 shares, the short-interest ratio is presently 14.0 days. Currently, 14.1% of the company's shares are short sold. View Urogen Pharma's Current Options Chain.

Some companies that are related to Urogen Pharma include Uniqure (QURE), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Insmed (INSM), Forty Seven (FTSV), Cambrex (CBM), Aurinia Pharmaceuticals (AUPH), Prestige Consumer Healthcare (PBH), Karuna Therapeutics (KRTX), Pacira Biosciences (PCRX), Epizyme (EPZM) and Eidos Therapeutics (EIDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Urogen Pharma investors own include Kite Pharma (KITE), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Nektar Therapeutics (NKTR), Neurocrine Biosciences (NBIX), AbbVie (ABBV), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), Intercept Pharmaceuticals (ICPT) and Immunomedics (IMMU).

(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Urogen Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wildcat Capital Management LLC (5.53%), Phoenix Holdings Ltd. (3.99%), Migdal Insurance & Financial Holdings Ltd. (3.53%), Credit Suisse AG (3.20%), State Street Corp (1.97%) and FMR LLC (1.51%). Company insiders that own Urogen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Institutional Ownership Trends for Urogen Pharma.

URGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Migdal Insurance & Financial Holdings Ltd., Goldman Sachs Group Inc., Bank Hapoalim BM, Private Advisors LLC, New York State Common Retirement Fund, Victory Capital Management Inc. and Quantbot Technologies LP. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Insider Buying and Selling for Urogen Pharma.

URGN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Phoenix Holdings Ltd., Wildcat Capital Management LLC, Jane Street Group LLC, Credit Suisse AG, State Street Corp, Meitav Dash Investments Ltd. and California Public Employees Retirement System. Company insiders that have bought Urogen Pharma stock in the last two years include Elizabeth A Barrett and Mark Schoenberg. View Insider Buying and Selling for Urogen Pharma.

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of URGN stock can currently be purchased for approximately $27.38.

Urogen Pharma has a market capitalization of $572.24 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.View Additional Information About Urogen Pharma.

The official website for Urogen Pharma is http://www.urogen.com/.

Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]